Genethon

Genethon company information, Employees & Contact Information

Explore related pages

Related company profiles:

Généthon est un laboratoire à but non lucratif, créé et soutenu par l’AFM-Téléthon depuis 1990. Après avoir été précurseur du déchiffrage du génome humain et de l’identification de gènes responsables des maladies génétiques, notre mission est de concevoir et de développer des traitements de thérapie génique pour des maladies rares (maladies neuromusculaires, déficits immunitaires, maladies du sang, du foie et de la vision). Plus de 240 chercheurs, médecins, pharmaciens, ingénieurs, techniciens de laboratoire et autres experts œuvrent avec audace et conviction pour relever les défis scientifiques, technologiques et cliniques. Basé à Évry-Courcouronnes, au cœur d’un pôle d’excellence en biothérapies, Généthon incarne un modèle unique au monde alliant recherche académique, innovation technologique et engagement associatif.

Company Details

Employees
307
Founded
-
Address
1, Rue De L'internationale, Évry,île-De-France 91000,france
Phone
+33 (0) 1 69 47 28 28
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Évry, Île-de-France
Looking for a particular Genethon employee's phone or email?

Genethon Questions

News

Genethon to Launch Pivotal Trial in Europe of GNT0004 a Low-Dose Microdystrophin Gene Therapy for Duchenne Muscular Dystrophy - Business Wire

Genethon to Launch Pivotal Trial in Europe of GNT0004 a Low-Dose Microdystrophin Gene Therapy for Duchenne Muscular Dystrophy Business Wire

Genethon and Eukarÿs announce a strategic partnership to - GlobeNewswire

Genethon and Eukarÿs announce a strategic partnership to GlobeNewswire

A Phase 3 Ready DMD Gene Therapy, a Clinical Trial to Offset AAV Neutralizing Antibodies, and an AI Inspired New Generation of Capsids Highlight Genethon’s 2024 Fall Milestones - Yahoo Finance

A Phase 3 Ready DMD Gene Therapy, a Clinical Trial to Offset AAV Neutralizing Antibodies, and an AI Inspired New Generation of Capsids Highlight Genethon’s 2024 Fall Milestones Yahoo Finance

Genethon Presents Two Year Consolidated Results of Its Gene Therapy Trial for Duchenne Muscular Dystrophy: Maintenance of Motor Functions and Significant, Sustained Reduction in CPK Levels in Patients Treated at the Effective Dose at ASGCT 2025 - Business Wire

Genethon Presents Two Year Consolidated Results of Its Gene Therapy Trial for Duchenne Muscular Dystrophy: Maintenance of Motor Functions and Significant, Sustained Reduction in CPK Levels in Patients Treated at the Effective Dose at ASGCT 2025 Business Wire

Genethon Presents Promising Results for Gene Therapy in DMD - AFM Téléthon

Genethon Presents Promising Results for Gene Therapy in DMD AFM Téléthon

Press Release Service: Genethon to Showcase the Latest Advances in Gene Therapies for Multiple Diseases at the ESGCT 31st Annual Congress October 22 – 25, 2024 in Rome, Italy - CRISPR Medicine News

Press Release Service: Genethon to Showcase the Latest Advances in Gene Therapies for Multiple Diseases at the ESGCT 31st Annual Congress October 22 – 25, 2024 in Rome, Italy CRISPR Medicine News

Genethon Celebrates Rare Disease Day by Highlighting New Technologies to Advance Gene Therapies and Bring Hope to Millions of Patients Worldwide - Business Wire

Genethon Celebrates Rare Disease Day by Highlighting New Technologies to Advance Gene Therapies and Bring Hope to Millions of Patients Worldwide Business Wire

Généthon, Eukarÿs Partnership Aims to Lower Manufacturing Costs for Gene Therapies - Genetic Engineering and Biotechnology News

Généthon, Eukarÿs Partnership Aims to Lower Manufacturing Costs for Gene Therapies Genetic Engineering and Biotechnology News

Genethon and Hansa Biopharma Launch Trial for Gene Therapy and Antibody Cleaving Enzyme Therapy Combination Treatment in Crigler-Najjar Syndrome - CGTLive®

Genethon and Hansa Biopharma Launch Trial for Gene Therapy and Antibody Cleaving Enzyme Therapy Combination Treatment in Crigler-Najjar Syndrome CGTLive®

BPS Publications - British Pharmacological Society | Journals

BPS Publications British Pharmacological Society | Journals

French Nonprofit Partners with Big American Name to Advance a Gene Therapy for Muscular Dystrophy - Labiotech.eu

French Nonprofit Partners with Big American Name to Advance a Gene Therapy for Muscular Dystrophy Labiotech.eu

World Duchenne Awareness Day: Genethon at the forefront of the fight against Duchenne muscular dystrophy - AFM Téléthon

World Duchenne Awareness Day: Genethon at the forefront of the fight against Duchenne muscular dystrophy AFM Téléthon

Muscle‐specific, liver‐detargeted adeno‐associated virus gene therapy rescues Pompe phenotype in adult and neonate Gaa−/− mice - Wiley Online Library

Muscle‐specific, liver‐detargeted adeno‐associated virus gene therapy rescues Pompe phenotype in adult and neonate Gaa−/− mice Wiley Online Library

Genethon Presents Positive Initial Results from a Phase 1/2/3 Trial of its Gene Therapy (GNT0004) for Duchenne Muscular Dystrophy at ASGCT Breakthroughs in Muscular Dystrophy in Chicago - Business Wire

Genethon Presents Positive Initial Results from a Phase 1/2/3 Trial of its Gene Therapy (GNT0004) for Duchenne Muscular Dystrophy at ASGCT Breakthroughs in Muscular Dystrophy in Chicago Business Wire

Gene Therapy: Two-Year Consolidated Results from Genethon’s Clinical Trial for Duchenne Muscular Dystrophy - AFM Téléthon

Gene Therapy: Two-Year Consolidated Results from Genethon’s Clinical Trial for Duchenne Muscular Dystrophy AFM Téléthon

Genethon Confirms 2-Year Efficacy in Duchenne Muscular Dystrophy Patients Treated With Its Low Dose Micro-Dystrophin Gene Therapy (GNT0004) at the ESGCT 32nd Annual Congress - Business Wire

Genethon Confirms 2-Year Efficacy in Duchenne Muscular Dystrophy Patients Treated With Its Low Dose Micro-Dystrophin Gene Therapy (GNT0004) at the ESGCT 32nd Annual Congress Business Wire

Duchenne Muscular Dystrophy: Start of the pivotal phase of Genethon's gene therapy trial - AFM Téléthon

Duchenne Muscular Dystrophy: Start of the pivotal phase of Genethon's gene therapy trial AFM Téléthon

Genethon and Hansa Biopharma launch a phase 2 clinical trial for Crigler-Najjar syndrome - AFM Téléthon

Genethon and Hansa Biopharma launch a phase 2 clinical trial for Crigler-Najjar syndrome AFM Téléthon

Markets - Medicine Hat News - FinancialContent

Markets - Medicine Hat News FinancialContent

Limb-Girdle Muscular Dystrophy Type 2I/R9: first gene therapy results - AFM Téléthon

Limb-Girdle Muscular Dystrophy Type 2I/R9: first gene therapy results AFM Téléthon

The Généthon laboratory, gene therapy pioneer, is 30 years old! - AFM Téléthon

The Généthon laboratory, gene therapy pioneer, is 30 years old! AFM Téléthon

Exposure to wild-type AAV drives distinct capsid immunity profiles in humans - JCI.org

Exposure to wild-type AAV drives distinct capsid immunity profiles in humans JCI.org

Charity and NIH funding related to Zolgensma - Knowledge Ecology International

Charity and NIH funding related to Zolgensma Knowledge Ecology International

A Novel Genome Editing Tool for Rare Hereditary Diseases - Inserm

A Novel Genome Editing Tool for Rare Hereditary Diseases Inserm

Efficacy of gene therapy demonstrated in canine and murine models of myotubular myopathy - Inserm

Efficacy of gene therapy demonstrated in canine and murine models of myotubular myopathy Inserm

Top Genethon Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant